Filtered By:
Therapy: Chemotherapy
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 70189 results found since Jan 2013.
Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs
Antimicrob Agents Chemother. 2023 Sep 19:e0048223. doi: 10.1128/aac.00482-23. Online ahead of print.ABSTRACTAntimicrobial resistance has made a sizeable impact on public health and continues to threaten the effectiveness of antibacterial therapies. Novel bacterial topoisomerase inhibitors (NBTIs) are a promising class of antibacterial agents with a unique binding mode and distinct pharmacology that enables them to evade existing resistance mechanisms. The clinical development of NBTIs has been plagued by several issues, including cardiovascular safety. Herein, we report a sub-series of tricyclic NBTIs bearing an amide link...
Source: Antimicrobial Agents and Chemotherapy - September 19, 2023 Category: Microbiology Authors: Chelsea A Mann Jessika J Carvajal Moreno Yanran Lu Sheri Dellos-Nolan Daniel J Wozniak Jack C Yalowich Mark J Mitton-Fry Source Type: research
Disrupting the infectious disease ecosystem in the digital precision health era innovations and converging emerging technologies
Antimicrob Agents Chemother. 2023 Sep 19:e0075123. doi: 10.1128/aac.00751-23. Online ahead of print.ABSTRACTThis commentary explores the convergence of precision health and evolving technologies, including the critical role of artificial intelligence (AI) and emerging technologies in infectious diseases (ID) and microbiology. We discuss their disruptive impact on the ID ecosystem and examine the transformative potential of frontier technologies in precision health, public health, and global health when deployed with robust ethical and data governance guardrails in place.PMID:37724872 | DOI:10.1128/aac.00751-23
Source: Antimicrobial Agents and Chemotherapy - September 19, 2023 Category: Microbiology Authors: Lilian M Abbo Ingrid Vasiliu-Feltes Source Type: research
The potential therapeutic applications of CRISPR/Cas9 in colorectal cancer
Curr Med Chem. 2023 Sep 15. doi: 10.2174/0929867331666230915103707. Online ahead of print.ABSTRACTThe application of the CRISPR-associated nuclease 9 (Cas9) system in tumor studies has led to the discovery of several new treatment strategies for colorectal cancer (CRC), including the recognition of novel target genes, the construction of animal mass models, and the identification of genes related to chemotherapy resistance. CRISPR/Cas9 can be applied to genome therapy for CRC, particularly regarding molecular-targeted medicines and suppressors. This review summarizes some aspects of using CRISPR/Cas9 in treating CRC. Furth...
Source: Current Medicinal Chemistry - September 19, 2023 Category: Chemistry Authors: Toktam Sahranavard Shima Mehrabadi Ghazaleh Pourali Mina Maftooh Hamed Akbarzade Seyed Mahdi Hassanian Majid Ghayour Mobarhan Gordon A Ferns Majid Khazaei Amir Avan Source Type: research
Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
CONCLUSIONS: We demonstrate an increasing incidence of SBA over the study period. These data can help inform shared decision-making for optimal management of locoregional breast cancer and raise awareness of secondary angiosarcoma.PMID:37725702 | DOI:10.1097/COC.0000000000001045
Source: Clinical Genitourinary Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Bonny Chau Elizabeth T Loggers Lee D Cranmer Harveshp Mogal Jeremy M Sharib Edward Y Kim Stephanie K Schaub Kelly G Paulson Hannah M Linden Jennifer M Specht Janice N Kim Sara H Javid Michael J Wagner Source Type: research
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial
CONCLUSIONS: We report RANK expression to be an independent predictive biomarker for response to NACT in luminal-like breast cancer patients.PMID:37725572 | DOI:10.1158/1078-0432.CCR-23-1801
Source: Clinical Genitourinary Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Theresa Link Jens-Uwe Blohmer Wolfgang D Schmitt Jan Dominik Kuhlmann Marianne Just Michael Untch Oliver Stotzer Peter A Fasching Marc Thill Mattea Reinisch Andreas Schneeweiss Pauline Wimberger Sabine Seiler Jens Huober Christian Jackisch Kerstin Rhiem C Source Type: research
Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair
CONCLUSIONS: In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increase the therapeutic success.PMID:37725585 | DOI:10.1158/1078-0432.CCR-23-1795
Source: Clinical Lung Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Anna Solta Kristiina Boettiger Ildik ó Kovács Christian Lang Zsolt Megyesfalvi Franziska Ferk Miroslav Mi šík Konrad Hoetzenecker Clemens Aigner Christian R Kowol Siegfried Knasmueller Michael Grusch Be áta Szeitz Melinda Rezeli Balazs Dome Karin Sch Source Type: research
Impact of adjuvant chemotherapy on long-term overall survival in patients with high-risk stage II colon cancer: a nationwide cohort study
CONCLUSION: 5-year overall survival was significantly higher in patients with high-risk stage II colon cancer treated with adjuvant chemotherapy compared with no chemotherapy. Adjuvant treatment was given to less than half of the patients who were eligible for it.PMID:37725517 | DOI:10.1080/0284186X.2023.2251086
Source: Acta Oncologica - September 19, 2023 Category: Cancer & Oncology Authors: Victoria Rosberg Mikkel Jessen Camilla Qvortrup Henry George Smith Peter-Martin Krarup Source Type: research
CAB39 promotes cisplatin resistance in bladder cancer via the LKB1-AMPK-LC3 pathway
In conclusion, our study shows that CAB39 counteracts the killing of cisplatin by enhancing the autophagy of BC cells to damaged mitochondria and other organelles to alleviate the damage of cells caused by harmful substances such as ROS.PMID:37726090 | DOI:10.1016/j.freeradbiomed.2023.09.017
Source: Free Radical Biology and Medicine - September 19, 2023 Category: Biology Authors: Dongyang Gao Runchang Wang Yuwen Gong Xiaoquan Yu Niu Qian Enguang Yang Guangrui Fan Junhai Ma Chaohu Chen Yan Tao Jianzhong Lu Zhiping Wang Source Type: research
Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis
CONCLUSIONS: First-line immunotherapy plus chemotherapy significantly improved PFS and OS in ES-SCLC patients without liver metastases compared to chemotherapy alone. However, patients with liver metastases did not experience comparable benefits.PMID:37724893 | DOI:10.18632/aging.205035
Source: Aging - September 19, 2023 Category: Biomedical Science Authors: Yan Lin Wei Jiang Cui-Yun Su Xin-Bin Pan Source Type: research
Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine
This study aimed to evaluate how chemotherapy changes immune system parameters and whether these changes influence survival outcomes. We sought to identify an easily accessible marker to help choose the appropriate treatment. Patients with PDAC who were suitable for systemic chemotherapy were eligible for the study. Peripheral blood samples were obtained at baseline and after two months of treatment. Lymphocyte subsets were measured using flow cytometry. Correlation with clinical features and survival analyses were performed. In total, 124 patients were enrolled in this study. Seventy patients were treated with mFOLFIRINOX...
Source: International Immunopharmacology - September 19, 2023 Category: Allergy & Immunology Authors: Skaiste Tulyte Dainius Characiejus Reda Matuzeviciene Ausra Janiulioniene Mantas Radzevicius Elena Jasiunaite Tadas Zvirblis Audrius Sileikis Source Type: research
Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair
CONCLUSIONS: In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increase the therapeutic success.PMID:37725585 | DOI:10.1158/1078-0432.CCR-23-1795
Source: Clinical Cancer Research - September 19, 2023 Category: Cancer & Oncology Authors: Anna Solta Kristiina Boettiger Ildik ó Kovács Christian Lang Zsolt Megyesfalvi Franziska Ferk Miroslav Mi šík Konrad Hoetzenecker Clemens Aigner Christian R Kowol Siegfried Knasmueller Michael Grusch Be áta Szeitz Melinda Rezeli Balazs Dome Karin Sch Source Type: research
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial
CONCLUSIONS: We report RANK expression to be an independent predictive biomarker for response to NACT in luminal-like breast cancer patients.PMID:37725572 | DOI:10.1158/1078-0432.CCR-23-1801
Source: Clinical Cancer Research - September 19, 2023 Category: Cancer & Oncology Authors: Theresa Link Jens-Uwe Blohmer Wolfgang D Schmitt Jan Dominik Kuhlmann Marianne Just Michael Untch Oliver Stotzer Peter A Fasching Marc Thill Mattea Reinisch Andreas Schneeweiss Pauline Wimberger Sabine Seiler Jens Huober Christian Jackisch Kerstin Rhiem C Source Type: research
Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
CONCLUSIONS: We demonstrate an increasing incidence of SBA over the study period. These data can help inform shared decision-making for optimal management of locoregional breast cancer and raise awareness of secondary angiosarcoma.PMID:37725702 | DOI:10.1097/COC.0000000000001045
Source: Clinical Breast Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Bonny Chau Elizabeth T Loggers Lee D Cranmer Harveshp Mogal Jeremy M Sharib Edward Y Kim Stephanie K Schaub Kelly G Paulson Hannah M Linden Jennifer M Specht Janice N Kim Sara H Javid Michael J Wagner Source Type: research
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial
CONCLUSIONS: We report RANK expression to be an independent predictive biomarker for response to NACT in luminal-like breast cancer patients.PMID:37725572 | DOI:10.1158/1078-0432.CCR-23-1801
Source: Clinical Breast Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Theresa Link Jens-Uwe Blohmer Wolfgang D Schmitt Jan Dominik Kuhlmann Marianne Just Michael Untch Oliver Stotzer Peter A Fasching Marc Thill Mattea Reinisch Andreas Schneeweiss Pauline Wimberger Sabine Seiler Jens Huober Christian Jackisch Kerstin Rhiem C Source Type: research
Consultation on UTUC II Stockholm 2022: diagnostic and prognostic methods —what’s around the corner?
ConclusionCurrent diagnostic methods for UTUC have shortcomings, especially concerning prognostication, which is important for personalized treatment decisions. There are several upcoming methods that may be of interest for UTUC. Most have been studied for urothelial carcinoma of the bladder, and it is important to keep in mind that UTUC is a different entity and not all methods are adaptable or applicable to UTUC.
Source: World Journal of Urology - September 19, 2023 Category: Urology & Nephrology Source Type: research
